Comment
Fraser et all in their original description of legionnaires' disease referred to three patients out of 182 with a WCC less than 2.0 x 109/1, two of whom died. Two other patients had WCCs of less than 6 0 x 109/1.
During his acute illness our patient had pancytopenia with bone marrow depression. We can only speculate on the part played by legionnaires' disease in producing hypoplastic anaemia. A toxic effect on the marrow may explain the pancytopenia during the acute phase of the illness. Its recurrence within a few weeks of clinical recovery, however, was unexpected and difficult to explain. Marrow hypoplasia might have been present before the development of legionnaires' disease, although this seems unlikely in view of the return of an almost normal blood profile after clinical recovery.
The role of co-trimoxazole in producing the hypoplastic anaemia is probably unimportant as the blood dyscrasias of this drug are quite distinct from that seen in our patient. Polyneuritis associated with azathioprine sensitivity reaction A reaction with fever, leucocytosis, arthralgia, myalgia, and rash may occur about two weeks after taking azathioprine.5 The mechanism of this response is unknown but the clinical pattern is similar to that of serum sickness. We report a case of reversible polyneuritis associated with other features of azathioprine sensitivity reaction.
Case report
A 40-year-old man presented with an 18-month history of weight loss, abdominal discomfort, diarrhoea without blood or mucus, aphthous ulcers, and night fever. Crohn's disease was diagnosed by finding rectal granulomata in a biopsy specimen and extensive disease throughout the small bowel on barium follow-through x-ray examination. Outpatient treatment with prednisolone 45 mg and azathioprine 125 mg (2 mg/kg body weight) daily was started. After 19 days he developed fever, arthralgia, and, within 48 hours, a rapidly progressive proximal muscle weakness such that he could not stand even with support. On admission he was febrile with a tachycardia of 140/min and blood pressure 100/50 mm Hg. There was no exacerbation of the Crohn's disease, which symptomatically had improved, but he had developed erythema nodosum over both shins. The proximal weakness was most definite in the hip girdle muscles, particularly the quadriceps (MRC grade 2), with some muscle tenderness but no fasciculation or reflex change and no sensory abnormality. He had a moderate normochromic anaemia of 11 4 g/dl, a neutrophil leucocytosis of 17-2 x 109/1 (17 200/mm3), an erythrocyte sedimentation rate of 64 mm in 1 h, a moderate hypoalbuminaemia of 25 g/l, and a serum alkaline phosphatase activity of 134 IU/l (normal 25-100 IU/l). The serum creatinine phosphokinase activity was normal. Electromyography, sampling quadriceps, showed a pattern of denervation with units of normal duration but low amplitude and moderate reduction in interference pattern. Motor conduction in the left peroneal nerve was reduced to 40 m/s (normal 42-1-63-5 m/s).
Azathioprine was stopped but prednisolone continued in the same dosage. The symptoms settled rapidly. Within four days there was no detectable weakness and the white cell count and alkaline phosphatase had returned to normal. He remained well. Five months later electromyograms were normal and conduction in the left peroneal nerve was 55 m/s.
Comment
Peripheral neuropathy has not been reported in association with Crohn's disease without secondary amyloid,2 but it is a recognised complication of hypersensitivity reactions to vaccination, immunisation, and drugs such as penicillin.3 In hypersensitivity reactions a subclinical neuropathy may be responsible for the common complaint of myalgia, and weakness may be masked by joint pain. Recognised patterns of peripheral neuropathy include mononeuritis, symmetrical motor or sensorimotor neuropathy, and brachial neuropathy, but there may also be central nervous system lesions or cranial nerve palsies, including optic neuritis. Azathioprine is now used in treating immune-mediated peripheral neuropathies and other immunological disorders of the nervous system (polymyositis, myasthenia, multiple sclerosis, polyarteritis). A drug-induced neuropathy should be considered when there is any change of neurological function associated with an azathioprine reaction. In at least one case azathioprine hypersensitivity was associated with "relapse" in a patient with dermatomyositis.5 The patient's serum creatinine phosphokinase activity remained normal and the increased weakness may have been due to a drug-related neuropathy.
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In view of the well-known poor prognosis of T-cell acute lymphoblastic leukaemia (ALL) compared with "common" ALL1 a difference in radiological bone changes might be expected. Analysis of recent data on incidence and width of the characteristic radiolucent metaphyseal bands in children at time of diagnosis appears to confirm this.
Patients, methods, and results
Routinely taken pretreatment skeletal survey films from 25 consecutive children diagnosed as ALL were "blindly" evaluated by one of us (EMS) and later correlated with the results of membrane marker studies of leukaemic cells aspirated from the bone marrow. The assessment of radiolucent metaphyseal bands was subjective since indefinite margins prevent exact measurement. Nevertheless, it was possible to apply the following criteria using an x-ray film centred over the knee joint in the antero-posterior position at 100-cm f cus-film distance. Radiolucent metaphyseal bands in the femur or tibia wiLth longitudinal dimensions up to 1 mm in width were scored as +, those between 1 and 2 mm as + +, and those over 2 mm as + + +. The results are shown in the table.
Comment
The results show a significantly lower incidence and width of the characteristic radiolucent metaphyseal bands at diagnosis in children Pretreatment radiological bone changes in 25 children diagnosed as suffering from acute lymphoblastic leukaemia (ALL) 
